ASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
|
|
- Brendan Griffin
- 5 years ago
- Views:
Transcription
1 Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy 2, Véronique Dorvaux 4, Jessica Michel 2, Thomas Gastinne 5, Cédric Rossi 3, Caroline Legouge 3, Cyrille Touzeau 5, Lucie Planche 5, Marion Loirat 5, Ingrid Lafon 3, Philippe Moreau 5, * ASBMT American Society for Blood and Marrow Transplantation 1 Hematology Department, University Hospital, Montreal, Canada 2 Hematology Department, University Hospital, Nancy, France 3 Hematology Department, University Hospital, Dijon, France 4 Hematology Department, University Hospital, Metz, France 5 Hematology Department, University Hospital, Nantes, France Article history: Received 5 September 2012 Accepted 19 November 2012 Key Words: Multiple myeloma Salvage therapy Autologous stem cell transplantation abstract Eighty-one patients treated with high-dose therapy and autologous stem cell transplantation (ASCT) as part of salvage therapy after a frontline ASCT were included in a retrospective analysis. The median time between the first and the salvage ASCT was 47 months. After salvage ASCT, 75 patients (93%) achieved at least a partial response, including 67% very good partial responses, and no toxic death was reported. Sixteen patients (20%) underwent consolidation therapy, whereas 30 patients (37%) underwent some form of maintenance therapy after salvage ASCT. For all patients, the median overall survival (OS) was 10 years from diagnosis and 4 years from salvage ASCT. The median progression-free survival (PFS) from the date of the first ASCT to the date of the first relapse was 40 months, and the median PFS from the date of salvage ASCT to the date of subsequent progression was 18 months. In the multivariate analysis of prognostic factors, three independent factors unfavorably affected PFS: a short duration of response to the first ASCT (cut-off value of 24 months), a response less than a very good partial response after salvage therapy, and no maintenance treatment after salvage ASCT. Age over 60 years and a short duration of response after the first ASCT were the two factors adversely affecting OS from the time of diagnosis and OS from the time of salvage ASCT. Our data show that salvage ASCT is a feasible option that should be routinely considered at the time of relapse for patients with a response duration of more than 2 years to frontline high-dose therapy. Ó 2013 American Society for Blood and Marrow Transplantation. INTRODUCTION Autologous stem cell transplantation (ASCT) after highdose melphalan is the treatment of choice for patients with symptomatic multiple myeloma (MM) who are younger than 65 years of age [1,2]. The incorporation of novel agents into this strategy has markedly improved progression-free survival (PFS) and overall survival (OS) of this group of patients over the last decade [3]. Nevertheless, almost all patients ultimately relapse, and no plateau is observed in the survival curves. At the time of disease recurrence, no one standard salvage approach is available; instead, various therapeutic options are used, including novel agentebased therapy, administered for a fixed duration of time or until progression. In a pivotal trial for the approval of bortezomib as monotherapy in patients with relapsed and refractory MM, the median PFS was 7 months [4], whereas in pivotal trials for the approval of lenalidomide in combination with dexamethasone in the same group of patients, the median time to progression was approximately 11 months [5,6]. A recent prospective, randomized, phase III study showed that a triplet combination of bortezomib, thalidomide, and dexamethasone achieved superior results compared with thalidomideedexamethasone alone in patients relapsing after ASCT, with a median time to progression of 19.5 versus 13.8 months, respectively [7]. This study suggested that combinations consisting of both an immunomodulatory drug and a proteasome inhibitor are a valuable option at the time of relapse. However, when a frozen graft is available, it is also possible to repeat high-dose therapy in patients who previously responded to the frontline application of high-dose melphalan and ASCT [8]. Over time, many reports have demonstrated the feasibility of this salvage strategy [9-19]. Most data are available from retrospective studies and are based on single-center experiences with small numbers of selected patients. In this setting, PFS has been shown to range from 7 to 22 months, and treatment-related mortality was acceptable, ranging from 0% to 8%. Various prognostic factors for prolonged PFS have been described, such as the duration of response to the first high-dose therapy [9,10,13-16,19] or the number of lines of therapy before salvage ASCT [9,10]. Here, we report the results of a retrospective analysis of salvage ASCT conducted in three French centers. Our goals were to identify prognostic factors for prolonged PFS and OS. Financial disclosure: See Acknowledgments on page 449. * Correspondence and reprint requests: Philippe Moreau, MD, Hematology Department, University Hospital Hôtel-Dieu, Place Ricordeau, Nantes, France. address: philippe.moreau@chu-nantes.fr (P. Moreau). y E. Lemieux and C. Hulin equally contributed to this work /$ e see front matter Ó 2013 American Society for Blood and Marrow Transplantation. METHODS In this retrospective analysis, all consecutive patients treated between 1995 and 2009 at centers of Nancy, Dijon, and Nantes with high-dose therapy and ASCT as part of salvage therapy after a frontline single or tandem ASCT and a subsequent relapse were included. To have a reliable
2 446 E. Lemieux et al. / Biol Blood Marrow Transplant 19 (2013) 445e449 follow-up time, patients who received salvage ASCT after January 1, 2010, were not included in the present analysis. The choice of salvage ASCT instead of other options was left to the treating physician and was also dependent on stem cell availability. In addition, patients had to present with adequate cardiac, lung, liver, or renal function, according to each center s policy. Response Criteria Response and progression were defined according to the International Myeloma Working Group criteria [20]. Briefly, a complete response was defined as negative immunofixation of serum and urine, disappearance of soft tissue plasmacytoma, and 5% plasma cells in the bone marrow. Very good partial response (VGPR) was defined as serum and urine M-protein detectable only by immunofixation or as a 90% or greater reduction in serum M-protein plus a urine M-protein level of <100 mg per 24 hours. Partial response (PR) was defined as a reduction in serum M-protein of at least 50% and by a reduction of at least 90% or an absolute value of <200 mg per 24 hours in urine M-protein. Stable disease was defined as not meeting any response criteria, and progressive disease was defined as a confirmed increase of 25% of M-protein from baseline. Relapse was defined as the reappearance of serum or urine M-protein or the development of new bone lesions, plasmacytoma, or hypercalcemia. Response post-asct was assessed at a maximum 100 days post transplantation, and patients were followed approximately every 3 months thereafter. Statistical Analysis PFS1 was defined from the date of the first ASCT to the date of first relapse or progression. PFS2 was defined from the date of salvage ASCT to the date of subsequent relapse or progression. OS rates were estimated from the date of diagnosis or from the date of relapse to the date of death or to the date of the last follow-up for patients who were still alive. Kaplan-Meier curves for PFS and OS were plotted and compared using a log-rank test. Predictive factors were determined by univariate analysis using Kaplan- Meier curves and the log-rank test. Only predictive factors with a significant result (P <.05) in univariate analysis entered multivariate analysis, using Cox regression. Statistical analysis was performed using SAS 9.3 (SAS Institute, Cary, NC). RESULTS From January 1995 to December 2009, 81 patients were treated with salvage ASCT. Patient characteristics at the time of diagnosis of symptomatic MM are shown in Table 1. The median time from diagnosis to the first ASCT was 4 months. Thirty-six percent of patients received tandem ASCT, 95% responded to high-dose therapy, and 58% received some form of maintenance therapy, the median duration of which was 16 months (range, 1 to 64). Patient characteristics at the time of salvage ASCT are listed in Table 2. The median time between the first and the salvage ASCT was 47 months (range, 13 to 168). Ninety-five percent of patients received induction therapy before salvage ASCT, which consisted of novel agentebased regimen in half, and four patients proceeded to ASCT without any salvage chemotherapy. Only 26 patients (32%) received more than 2 lines of therapy before salvage ASCT. At the time of salvage ASCT, 67 patients (83%) had achieved at least a PR to induction therapy, 10 (12%) had not responded to induction, and 4 were in an untreated relapse. Fifty-eight of 81 patients (72%) received stem cells that had been harvested before the first ASCT. For 23 patients (28%), stem cells were harvested after the first relapse using granulocyte colony-stimulating factor alone (13 patients), cyclophosphamide þ granulocyte colony-stimulating factor (6 patients), or plerixafor þ granulocyte colony-stimulating factor (4 patients). After salvage ASCT, 75 patients (93%) achieved at least a PR, including 67% VGPR, and no toxic death was reported. Sixteen patients (20%) received consolidation therapy, whereas 30 (37%) received some form of maintenance therapy after salvage ASCT. Table 1 Patient Characteristics at Diagnosis and First High-Dose Therapy Step Variable (N ¼ 81) Median age at diagnosis (range) 55 (30-67) Male 47 (58%) Female 34 (42%) Durie-Salmon stage I 4 (5%) II 9 (11%) III 68 (84%) International Staging System 1 40 (49%) 2 22 (27%) 3 14 (17%) Missing data 5 (7%) Isotype IgG 53 (65%) IgA 10 (12%) Light chain 18 (23%) Induction regimen before first ASCT VAD 69 (85%) VMCP-VBAP 4 (5%) Bortezomib-dexamethasone 8 (10%) Conditioning regimen before first ASCT Melphalan 200 mg/m 2 40 (49%) Melphalan 140 mg/m 2 23 (28%) Melphalan 140 þ 8 Gy total body irradiation 12 (15%) Other 6 (7%) Tandem ASCT 29 (36%) Response after first high-dose therapy VGPR 58 (72%) PR 19 (23%) SD 4 (5%) Maintenance therapy after first high-dose therapy Interferon-a 24 (30%) Thalidomide 13 (16%) Lenalidomide 6 (7%) Other 4 (5%) None 34 (42%) VAD indicates vincristine, adriamycin, dexamethasone; VMCP-VBAP, vincristine, melphalan, cyclophosphamide, prednisone-vincristine, carmustine, doxorubicin, prednisone; SD, stable disease. Survival and Prognostic Factors The median follow-up time for living patients was 7 years (range, 2.1 to 16.6). The median OS was 10 years from diagnosis and 4 years from salvage ASCT (Figure 1). The median PFS1 was 40 months (range, 10 to 152), and the median PFS2 was 18 months (range, 2 to 64) (Figure 1). The duration of the second response was found to be related to PFS1: The median PFS2 was 26.4 months in patients experiencing their first relapse more than 40 months after the first ASCT versus 14 months in patients relapsing within the first 40 months after their first ASCT, P ¼.001 (Figure 2). A cut-off value of 24 months for relapse after the first ASCT was also found to significantly affect PFS2, with a duration of second response of 9 versus 18 months (P ¼.0096) for patients relapsing within 24 months versus those with a relapse more than 24 months after the first ASCT. The analysis was not performed for a shorter duration of first response due to the small number of patients relapsing within 18 months after their first ASCT. In addition, the duration of response after the first ASCT also affected OS. The median OS rate from salvage therapy was longer in patients relapsing 24 or 40 months after their first ASCT versus others (median 7.2 and 7.3 versus 2.4 and 3.4 years, respectively; P <.05). The duration of response after salvage ASCT was also significantly affected by the use of maintenance therapy (Figure 3). Results of the univariate analysis of prognostic factors are presented in Table 3. In the multivariate analysis,
3 E. Lemieux et al. / Biol Blood Marrow Transplant 19 (2013) 445e Table 2 Salvage ASCT Variable (N ¼ 81) Median age at the time of salvage ASCT (range) 58 (35-71) Novel induction regimen before salvage ASCT VAD 23 (29%) Bortezomib-dexamethasone or lenalidomidedexamethasone 26 (32%) or thalidomide-dexamethasone VTD or VRD 10 (12%) Others 18 (22%) None 4 (5%) Conditioning regimen before salvage ASCT Melphalan 220 mg/m 2 12 (15%) Melphalan 200 mg/m 2 45 (56%) Melphalan 140 mg/m 2 9 (11%) Melphalan þ busulphan 2 (2%) Others 13 (16%) Response after salvage ASCT VGPR 54 (67%) PR 21 (26%) SD 5 (6%) PD 1 (1%) Transplantation-related death 0 Consolidation therapy after salvage ASCT Bortezomib-dexamethasone 6 (7%) VTD 2 (3%) VRD 4 (5%) Lenalidomide-dexamethasone 4 (5%) None 65 (80%) Maintenance therapy after salvage ASCT Thalidomide 11 (14%) Lenalidomide 12 (15%) Bortezomib 3 (4%) Other 4 (5%) None 51 (63%) VAD indicates vincristine, adriamycin, dexamethasone; VTD, bortezomibthalidomide-dexamethasone; VRD, bortezomib-lenalidomide-dexamethasone; SD, stable disease; PD, progressive disease. three independent factors unfavorably affected PFS: a short duration of response to the first ASCT, a response less than a VGPR after salvage therapy, and no maintenance treatment after salvage ASCT. Age over 60 years and a short duration of response after the first ASCT were the two factors adversely affecting OS from the time of diagnosis and OS from the time of salvage ASCT (Table 4). DISCUSSION Currently, there is no broadly accepted standard treatment for patients with relapsed/refractory MM [21]. For the Figure 2. Progression-free survival rates after salvage ASCT according to the duration of response after the first ASCT (<40 or >40 months). selection of an appropriate treatment strategy at this stage, both disease-related and patient-related factors and, importantly, the type of previous therapy need to be considered [21-25]. Disease-related factors include the quality and duration of response to previous therapies and the aggressiveness of the relapse, whereas patient-related factors comprise pre-existing toxicities, comorbid conditions, quality of life, age, and performance status [21-25]. Regarding previous therapies, it is important to take into account if the patient has been exposed to alkylators or to the novel agents, immunomodulatory drugs and proteasome inhibitors, and if this was alone or in combination, to define the best strategy [21-26]. Intensive therapy can always be considered at this stage [21]. Although allogeneic transplantation shows limited clinical benefit for the treatment of patients with relapsed/ refractory MM [27], available data suggest that a second autologous transplantation may be beneficial and well tolerated for some patients in this setting [21-23]. The overall response rates in studies range from 55% to 69%, with a 100- day mortality rate <10% [8-19]. However, the small sample size used in these studies complicates the identification of the ideal candidate for this treatment approach. Most reports suggest that the duration of the first response to ASCT is the major prognostic factor [8-19]. In the current retrospective study, we confirm that salvage ASCT at the time of relapse is a valuable and feasible option. Response rates were high, with more than 90% of Figure 1. Progression-free and overall survival rates. Figure 3. Progression-free survival rates after salvage ASCT according to maintenance therapy.
4 448 E. Lemieux et al. / Biol Blood Marrow Transplant 19 (2013) 445e449 Table 3 Univariate Analysis of Variables Unfavorably Affecting Progression-Free and Overall Survival Rates Variable (P <.05) HR 95% CI P Value Progression-free survival after salvage ASCT Duration of response after first ASCT < 24 mo 2.40 [1.21, 4.76].01 Duration of response after first ASCT < 40 mo 2.78 [1.62, 4.77].0002 Response after salvage ASCT < VGPR 2.48 [1.42, 4.10].001 No maintenance therapy after salvage ASCT 3.32 [1.76, 6.29].0002 Overall survival from diagnosis Age > 60 y 5.09 [2.33, 11.10] <.0001 b 2 -microglobulin at diagnosis > 3.5 mg/l 2.21 [1.12, 4.35].02 Duration of response after first ASCT < 24 mo 6.85 [3.27, 14.86] <.0001 Duration of response after first ASCT < 40 mo 7.08 [3.35, 14.99] <.0001 Response after first ASCT < VGPR 2.80 [1.48, 5.28] Response after salvage ASCT < VGPR 3.81 [2.00, 7.23] <.0001 No maintenance therapy after salvage ASCT 2.83 [1.23, 6.49].01 Overall survival from salvage ASCT Age > 60 y 2.89 [1.43, 5.86].003 Duration of response after first ASCT < 24 mo 3.65 [1.77, 7.53].0004 Duration of response after first ASCT < 40 mo 3.47 [1.68, 7.18].0008 Response after first ASCT < VGPR 2.25 [ ].01 Response after salvage ASCT < VGPR 2.76 [1.43, 5.31].002 HR indicates hazard ratio; CI, confidence interval. patients achieving at least a PR, with no transplantationrelated mortality. Our results thereby confirm those reported by various groups [9-19]. In addition, similar to what has previously been described, we show that the duration of response to the first ASCT is the major prognostic factor for both PFS and OS. In our series, a duration of response of at least 24 months to the first intensive therapy was associated with a longer PFS and OS. This cut-off value of 24 months was also described in a series of 81 patients treated at the Princess Margaret Hospital, Toronto, Ontario, Canada [16]. Different cut-off values, ranging from 12 to 24 months, have already been proposed by several investigators [9,15,19]. Interestingly, we found that a response of less than VGPR after salvage ASCT was an independent adverse prognostic factor for PFS. It is only the second time this factor, which is a known prognostic factor in the frontline ASCT setting [3], has been described to be important in the context of salvage ASCT [16]. Of note, we were able to analyze the impact of maintenance therapy after salvage ASCT and showed for the first time that maintenance might significantly prolong the duration of response. The role of maintenance in the frontline setting is a matter of controversy [28], despite the overwhelming strong evidence of an improvement in PFS when immunomodulatory drugs are administered after upfront ASCT [29,30]. Our findings will feed the debate on the role of maintenance in the setting of salvage ASCT. Of note in our analysis is that some patients received an autograft that had been cryopreserved and stored for 10 years before the salvage ASCT [8]. There are a number of limitations to our study. First, it was not an intent-to-treat analysis, and we lack precise data on how many patients were excluded from salvage ASCT because of comorbidity, an insufficient amount of stem cells, or progressive and/or refractory disease. This selection bias is the most important shortcoming. Second, the study is related to the long period of accrual, which explains the heterogeneity in the treatment received by the patients, both as part of frontline therapy and at the time of relapse. Clearly, the role of salvage ASCT has to be re-examined in the context of novel agents. Moreover, we collected cytogenetic data in only some patients, and salvage therapies have to be evaluated, if possible, with this information available. Nevertheless, our data show that salvage ASCT is a feasible option that should be routinely considered at the time of relapse for patients with a response duration of more than 2 years to frontline high-dose therapy. The feasibility of salvage ASCT might also be improved in the future with novel strategies of stem cell collection, such as the use of plerixafor, which allows the collection of stem cells in patients previously exposed to high-dose therapy [31]. Table 4 Multivariate Cox Regression Analysis of Variables Unfavorably Affecting Progression-Free and Overall Survival Rates Variable (P <.05) HR 95% CI P Value Progression-free survival after salvage ASCT Duration of response after first ASCT < 24 mo 2.25 [1.02, 4.98].04 Duration of response after first ASCT < 40 mo 2.46 [1.40, 4.32].001 Response after salvage ASCT < VGPR 1.97 [1.02, 3.80].04 No maintenance therapy after salvage ASCT 3.40 [1.72, 6.69].0004 Overall survival from diagnosis Age > 60 y 4.00 [1.50, 10.71].006 Duration of response after first ASCT < 24 mo [3.98, 55.70] <.0001 Duration of response after first ASCT < 40 mo 4.67 [2.04, 10.70].0003 Overall survival from salvage ASCT Age > 60 y 3.62 [1.39, 9.42].008 Duration of response after first ASCT < 24 mo 8.25 [2.93, 23.22] <.0001 Duration of response after first ASCT < 40 mo 4.45 [1.93, 10.24].0004 HR indicates hazard ratio; CI, confidence interval.
5 E. Lemieux et al. / Biol Blood Marrow Transplant 19 (2013) 445e ACKNOWLEDGMENTS Financial disclosure: The authors have nothing to disclose. REFERENCES 1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;3335: Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29: Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110: Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357: Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357: Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM randomized phase III trial from the chronic leukemia working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30: Gertz MA. Stem cell transplant: an effective salvage therapy for multiple myeloma. Leuk Lymph. 2011;52: Olin RL, Vogl DT, Porter DL, et al. Second auto-sct is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009;43: Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012;118: Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol. 2006;81: Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006;106: Chow AW, Lee CH, Hiwase DK, et al. Relapsed multiple myloma: who benefits from salvage autografts? Blood (ASH Annual Meeting Abstracts) 2011;118:abstr Saad AA, Vesole DH, Le-Rademacher J, et al. Second autologous transplants for multiple myeloma relapse after a prior autologous transplantda report from the Center for International Blood and Marrow Transplant Research. Blood (ASH Annual Meeting Abstracts) 2011;118:abstr Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006;91: Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18: Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymph. 2009;50: Freytes CO, Vesole DH, Zhong X, et al. Second transplants in relapsed multiple myeloma: autologous versus non-myeloablative/reduced intensity allogenic transplantation. Blood (ASH Annual Meeting Abstracts) 2011;118:abstr Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymph. 2011;52: Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20: Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012;49(suppl 1): S16-S Bird JM, Owen RG, D Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma. Br J Haematol. 2011;154: Offidani M, Corvatta L, Morabito F, et al. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. Expert Opin Invest Drugs. 2011;20: Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17: Shah N, Lonial S. Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel-agents and high-dose chemotherapy and autologous stemcell transplantation. Hematol Am Soc Hematol Educ Progr. 2010;1: Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and retreatment approaches in the era of novel agents. Leukemia. 2012; 26: Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28: Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119: Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366: McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366: Giralt S, Stadtmauer EA, Harousseau JL, et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:
VI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationSecond Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda, 1 Joseph Mikhael, 2 Andrew Winter, 1 Norman
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationautologous, chemotherapy, high dose, lenalidomide, maintenance, myeloma, relapse, salvage, stem cell, survival, transplant
Received: 20 September 2017 Revised: 8 December 2017 Accepted: 11 December 2017 DOI: 10.1002/hon.2490 ORIGINAL RESEARCH ARTICLE Prolonged survival after second autologous transplantation and lenalidomide
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationKEY WORDS: Multiple myeloma, Complete remission, Prognostic factor, Overall survival, Autologous stem cell transplantation
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Jin Seok Kim,
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationUltra High-Risk Myeloma
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGIC MALIGNANCIES Ultra High-Risk Myeloma Hervé Avet-Loiseau 1 1 Laboratoire d Hématologie, Institut de Biologie, Nantes, France Ultra high-risk myeloma
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More information"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
More informationJunru Liu*, Juan Li*, Beihui Huang, Dong Zheng, Mei Chen, Zhenhai Zhou, Duorong Xu, Waiyi Zou
Original Article Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Junru Liu*, Juan
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationBLOOD RESEARCH. Ja Min Byun 1,2, Jayoun Lee 3, Sang-Jin Shin 3, Minjoo Kang 3, Sung-Soo Yoon 2, Youngil Koh 2 ORIGINAL ARTICLE INTRODUCTION
BLOOD RESEARCH VOLUME 53 ㆍ NUMBER 2 June 2018 ORIGINAL ARTICLE Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationBortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
VOLUME 45 ㆍ NUMBER 3 ㆍ September 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma Se
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Frequently Asked Questions
Downloaded on 08 15 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org Oncology
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationBiology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 12:837-844 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1208-0006$32.00/0 doi:10.1016/j.bbmt.2006.04.006 New Staging Systems
More informationMedical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012
Medical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012 Support AL Amyloidosis (Light Chain Amyloidosis) Effective Date: 01/01/2013 Document: ARB0413:01 Revision Date: 10/24/2012 Code(s):
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationKEY WORDS: Autologous stem cell transplantation, Salvage, Myeloma INTRODUCTION
Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry Gordon Cook,
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationSecond Primary Cancers in Myeloma: A Status Report. February 2011
Second Primary Cancers in Myeloma: A Status Report February 2011 During the past few weeks members of the International Myeloma Working Group (IMWG) have been considering and discussing results presented
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationEffective response with bortezomib retreatment in relapsed multiple myeloma
Published 27 April 2012, doi:10.4414/smw.2012.13562 Cite this as: Effective response with bortezomib retreatment in relapsed multiple myeloma A multicentre retrospective survey in Switzerland 1 Christian
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationProtocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis
Protocol Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis (80142) Medical Benefit Effective Date: 04/01/13 Next Review Date: 07/15 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationKeywords: multiple myeloma; autologous; allogeneic stem cell transplantation. Summary:
Bone Marrow Transplantation, (1999) 23, 317 322 1999 Stockton Press All rights reserved 268 3369/99 $12. http://www.stockton-press.co.uk/bmt Induction therapy with vincristine, adriamycin, dexamethasone
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Policy Number: 8.01.17 Last Review: 2/2018 Origination: 12/2001 Next Review: 2/2019 Policy
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationMyeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco
Myeloma: Are We on the Brink of a Cure? Jeffrey Wolf, MD Director, Myeloma Program University of California, San Francisco Survival in Myeloma IFM DFCI; 2015 2011-14 2001-10 1961-70 1991-2000 Kumar S.
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationRetrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
930 Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO and WENMING CHEN Department
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationChim et al. Journal of Hematology & Oncology 2012, 5:28
Chim et al. Journal of Hematology & Oncology 2012, 5:28 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationOriginal article. Introduction
Original article Annals of Oncology 15: 134 138, 2004 DOI: 10.1093/annonc/mdh026 Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil):
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationAge 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant Parneet K. Cheema, Sahar Zadeh, Vishal Kukreti, Donna Reece,
More informationHodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. Citation Annals of Hematology, 2013, v. 92 n. 6, p.
Title Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. Author(s) Chim, JCS; Choi, PT; Lee, WK Citation Annals of Hematology, 2013, v. 92 n. 6, p. 855-857 Issued
More information